0001102624-16-003396.txt : 20160920 0001102624-16-003396.hdr.sgml : 20160920 20160920161834 ACCESSION NUMBER: 0001102624-16-003396 CONFORMED SUBMISSION TYPE: D/A PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20160920 DATE AS OF CHANGE: 20160920 EFFECTIVENESS DATE: 20160920 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Boston Therapeutics, Inc. CENTRAL INDEX KEY: 0001473579 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 270801073 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D/A SEC ACT: 1933 Act SEC FILE NUMBER: 021-269587 FILM NUMBER: 161894084 BUSINESS ADDRESS: STREET 1: 33 SOUTH COMMERCIAL STREET CITY: MANCHESTER STATE: NH ZIP: 03101 BUSINESS PHONE: 978-886-0421 MAIL ADDRESS: STREET 1: 33 SOUTH COMMERCIAL STREET CITY: MANCHESTER STATE: NH ZIP: 03101 FORMER COMPANY: FORMER CONFORMED NAME: AVANYX Therapeutics, Inc. DATE OF NAME CHANGE: 20091001 D/A 1 primary_doc.xml X0707 D/A LIVE 0001473579 Boston Therapeutics, Inc. 354 Merrimack Street, #4 Lawrence MA MASSACHUSETTS 01843 603-935-9799 DELAWARE AVANYX Therapeutics, Inc. Corporation true Carl W. Rausch 354 Merrimack Street, #4 Lawrence MA MASSACHUSETTS 01843 Executive Officer CEO Rom Eliaz 354 Merrimack Street, #4 Lawrence MA MASSACHUSETTS 01843 Director Chairman Colin Neill 354 Merrimack Street, #4 Lawrence MA MASSACHUSETTS 01843 Director Alan Hoberman 354 Merrimack Street, #4 Lawrence MA MASSACHUSETTS 01843 Director Conroy Chi-Heng Cheng 354 Merrimack Street, #4 Lawrence MA MASSACHUSETTS 01843 Director Pharmaceuticals Decline to Disclose 06b true 0001102624-16-003316 2016-08-12 false true true true true Convertible Promissory Notes and Warrants false 25000 Maxim Group, LLC 120708 None None 405 Lexington Avenue New York NY NEW YORK 10174 AR ARKANSAS IL ILLINOIS NY NEW YORK CA CALIFORNIA MO MISSOURI LA LOUISIANA VA VIRGINIA NJ NEW JERSEY NM NEW MEXICO AL ALABAMA TX TEXAS FL FLORIDA IA IOWA PA PENNSYLVANIA false 2000000 1600000 400000 false 28 160000 0 Placement agent will receive a 10% commission and a warrant to purchase a number of shares equal to 10% of the aggregate number of shares sold. 100000 true Working capital. false Boston Therapeutics, Inc. /s/ Carl W. Rausch Carl W. Rausch Chief Executive Officer 2016-09-19